Zenitar

Founded in 2019 and headquartered in Chengdu, China, Zenitar is a clinical-stage biotech company dedicated to advancing AI-driven, structure-based small molecule discovery and clinical pipeline development across oncology, autoimmune diseases, and inflammatory disorders. Leveraging differentiated mechanisms to drive first-in-class or best-in-class potential, the Company's pipeline includes multiple assets in Phase II clinical trials, with a focus on addressing high unmet medical needs. The Company is currently in its B+ round of financing.